Myocardial and Pericardial Toxicity Associated With Immune Checkpoint Inhibitors in Cancer Patients

We recount a single-center experience with cardiac immunity-related adverse effects in patients treated with immune checkpoint inhibitors. Of 2,830 patients, 9 patients (0.3%) developed cardiac immunity-related adverse effects (4 cases of cardiomyopathies, 2 of myocarditis, 2 of acute pericarditis,...

Full description

Bibliographic Details
Main Authors:	Johnny Chahine, MD, Patrick Collier, MD, PhD, Anjli Maroo, MD, W.H. Wilson Tang, MD, Allan L. Klein, MD
Format:	Article
Language:	English
Published:	Elsevier 2020-02-01
Series:	JACC: Case Reports
Subjects:	cardiotoxicity immune checkpoint inhibitors immunity-related adverse events
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666084919306916

id	doaj-aabe2c39721c4f3684199302b525f04f
record_format	Article
spelling	doaj-aabe2c39721c4f3684199302b525f04f2021-06-07T06:55:21ZengElsevierJACC: Case Reports2666-08492020-02-0122191199Myocardial and Pericardial Toxicity Associated With Immune Checkpoint Inhibitors in Cancer PatientsJohnny Chahine, MD0Patrick Collier, MD, PhD1Anjli Maroo, MD2W.H. Wilson Tang, MD3Allan L. Klein, MD4Department of Medicine, Cleveland Clinic Foundation, Cleveland, OhioCenter for the Diagnosis and Treatment of Pericardial Diseases, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OhioDepartment of Cardiovascular Medicine, Cleveland Clinic Foundation Fairview Hospital, Cleveland, OhioDepartment of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OhioCenter for the Diagnosis and Treatment of Pericardial Diseases, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio; Address for correspondence: Dr. Allan L. Klein, Mail Code J1-5, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195.We recount a single-center experience with cardiac immunity-related adverse effects in patients treated with immune checkpoint inhibitors. Of 2,830 patients, 9 patients (0.3%) developed cardiac immunity-related adverse effects (4 cases of cardiomyopathies, 2 of myocarditis, 2 of acute pericarditis, and 1 of large pericardial effusion). Disease profiles, hospital courses, and outcomes are reported. (Level of Difficulty: Advanced.)http://www.sciencedirect.com/science/article/pii/S2666084919306916cardiotoxicityimmune checkpoint inhibitorsimmunity-related adverse events
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Johnny Chahine, MD Patrick Collier, MD, PhD Anjli Maroo, MD W.H. Wilson Tang, MD Allan L. Klein, MD
spellingShingle	Johnny Chahine, MD Patrick Collier, MD, PhD Anjli Maroo, MD W.H. Wilson Tang, MD Allan L. Klein, MD Myocardial and Pericardial Toxicity Associated With Immune Checkpoint Inhibitors in Cancer Patients JACC: Case Reports cardiotoxicity immune checkpoint inhibitors immunity-related adverse events
author_facet	Johnny Chahine, MD Patrick Collier, MD, PhD Anjli Maroo, MD W.H. Wilson Tang, MD Allan L. Klein, MD
author_sort	Johnny Chahine, MD
title	Myocardial and Pericardial Toxicity Associated With Immune Checkpoint Inhibitors in Cancer Patients
title_short	Myocardial and Pericardial Toxicity Associated With Immune Checkpoint Inhibitors in Cancer Patients
title_full	Myocardial and Pericardial Toxicity Associated With Immune Checkpoint Inhibitors in Cancer Patients
title_fullStr	Myocardial and Pericardial Toxicity Associated With Immune Checkpoint Inhibitors in Cancer Patients
title_full_unstemmed	Myocardial and Pericardial Toxicity Associated With Immune Checkpoint Inhibitors in Cancer Patients
title_sort	myocardial and pericardial toxicity associated with immune checkpoint inhibitors in cancer patients
publisher	Elsevier
series	JACC: Case Reports
issn	2666-0849
publishDate	2020-02-01
description	We recount a single-center experience with cardiac immunity-related adverse effects in patients treated with immune checkpoint inhibitors. Of 2,830 patients, 9 patients (0.3%) developed cardiac immunity-related adverse effects (4 cases of cardiomyopathies, 2 of myocarditis, 2 of acute pericarditis, and 1 of large pericardial effusion). Disease profiles, hospital courses, and outcomes are reported. (Level of Difficulty: Advanced.)
topic	cardiotoxicity immune checkpoint inhibitors immunity-related adverse events
url	http://www.sciencedirect.com/science/article/pii/S2666084919306916
work_keys_str_mv	AT johnnychahinemd myocardialandpericardialtoxicityassociatedwithimmunecheckpointinhibitorsincancerpatients AT patrickcolliermdphd myocardialandpericardialtoxicityassociatedwithimmunecheckpointinhibitorsincancerpatients AT anjlimaroomd myocardialandpericardialtoxicityassociatedwithimmunecheckpointinhibitorsincancerpatients AT whwilsontangmd myocardialandpericardialtoxicityassociatedwithimmunecheckpointinhibitorsincancerpatients AT allanlkleinmd myocardialandpericardialtoxicityassociatedwithimmunecheckpointinhibitorsincancerpatients
_version_	1721391966849073152

Myocardial and Pericardial Toxicity Associated With Immune Checkpoint Inhibitors in Cancer Patients

Similar Items